Millipore Corp

Millipore — Merger or Acquisition (March 2010)

11 slides from Millipore's merger presentation, Mar 1, 2010

  1. Slide 1: All Employee Teleconference March 1st, 2010

    All Employee Teleconference March 1 st , 2010

  2. Slide 2: Forward Looking & Cautionary Statements

    Forward Looking & Cautionary Statements • The Information in this document may contain “forward-looking statements”. Forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “will” or words of similar meaning and in

  3. Slide 3: Agenda

    Agenda • What’s happening? • Why does this make sense? • Millipore in the short term • Millipore in the future

  4. Slide 4: What's happening?

    What’s happening? • Merck KGaA entered into a definitive agreement to acquire all outstanding Millipore shares for US$107 per share in cash, or a total transaction value (including net debt) of approximately US$7.2 bn • Represents significant shareholder value and new opportunities for Millipore emp

  5. Slide 5: Proposal: Merck KGaA & Millipore

    Proposal: Merck KGaA & Millipore

  6. Slide 6: Why does this make sense for Merck?

    Why does this make sense for Merck? • Contributes complementary high-margin specialty products with an attractive growth profile • Creates a € 2bn (~US$ 2.75 bn) world class partner for the Life Science sector • Provides significant scale in high-growth bioscience and bioproduction segments • Compre

  7. Slide 7: Why does this make sense for Millipore?

    Why does this make sense for Millipore? • Combines the strong R&D capabilities and global presence of both companies to expand our global reach, innovation capacity, customer value creation and risk diversification • Builds upon Millipore’s strong brand and a proven track record of sustainable and p

  8. Slide 8: Combined R&D capabilities creates powerful innovation platform

    Combined R&D capabilities creates powerful innovation platform • Pro forma annual R&D budget of EUR 123m focused on products for pharma and biotech customers • Increased scale helps to improve return on investment in new technologies, and diversifies risk • Make effective use of existing biopharma c

  9. Slide 9: How does this benefit our customers?

    How does this benefit our customers? • Customers in the pharma and biopharmaceutical industries will benefit from a comprehensive product offering, cutting-edge technologies and enhanced distribution platforms. • Two world class teams will join forces to open up new growth opportunities across the w

  10. Slide 10: Millipore in the short term

    Millipore in the short term • Business as Usual • Please continue to provide customers with the same high quality of products, services and expertise • No immediate impact on employees, including pay, benefits and organizational structure • We’ll keep you informed throughout the process

  11. Slide 11: Millipore Future

    Millipore Future • You are the Millipore brand and one of the most valuable assets we have! • Among some of the most talented employees in the industry • Exciting opportunities for employees • Broader, more diversified suite of products and technologies for customers • Enhanced shareholder value

Millipore — Merger or Acquisition (March 2010) on 6ix